Corporate Banner
Satellite Banner
Genotyping & Gene Expression
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Proteome Sciences to Develop Cancer Pathway Profiling Assays

Published: Monday, June 17, 2013
Last Updated: Monday, June 17, 2013
Bookmark and Share
New MS3 TMT® mass spectrometry technique to determine relative quantitation of proteins in multiple samples simultaneously.

Proteome Sciences has announced its largest contract to date, a technology agreement with Thermo Fisher Scientific, valued at $2.1million by Proteome Sciences, to develop advanced methods to profile changes in key cancer pathways.

Proteome Sciences will provide Thermo Fisher with access to its patents covering a three-stage mass spectrometry (MS3) fragmentation methodology to deliver significantly improved analysis and accuracy.

Proteome Sciences will receive cash and Thermo Fisher will provide a no-cost lease for mass spectrometry equipment for Proteome Sciences to develop the pathway assays.

In addition Proteome Sciences will continue to develop advanced 20 and 30-plex Tandem Mass Tags (TMT®) for Thermo Fisher for the next additions to the TMT® range of tags.

The new MS3 TMT® (three-stage MS Tandem Mass Tag) mass spectrometry technique is a breakthrough mass spectrometry based workflow, enabling mass spectrometers to determine relative quantitation of proteins in multiple samples simultaneously and with improved accuracy.

“We are at a critical juncture toward the development of personalized medicine which requires high-resolution maps of the protein networks regulating disease,” said Dr. Ian Pike, Chief Operating Officer at Proteome Sciences.

Dr. Pike continued, “The combination of the highest sample multiplexing rates from TMT with the industry-leading Thermo Scientific Orbitrap mass spectrometer enables us to provide an unrivalled platform to investigate subtle but significant changes in the proteome.”

Proteome Sciences will leverage the combined power of TMT® and Orbitrap® technology to develop an expanded range of mass spectrometry assays for the pharmaceutical industry.

Through its SysQuant® workflows, Proteome will profile the low-level changes in activity of key cancer signalling pathways to facilitate optimal drug selection across a range of solid tumours.

This will enable clinicians to provide real-time patient management and the ability, for the first time, to deliver truly personalized medicine.

“Life sciences researchers today need to perform high-quality relative quantitation of many samples quickly,” said Ian Jardine, Chief Technology Officer, Chromatography and Mass Spectrometry, Thermo Fisher Scientific.

Jardine continued, “MS3 TMT® technology greatly improves quantitative accuracy and throughput, while Orbitrap® technology dramatically increases depth and quality of data. This agreement offers customers a new paradigm in proteomics research.”

“Our agreement with Thermo Fisher sets a new benchmark to establish and apply novel diagnostic and prognostic strategies in healthcare management,” said Christopher Pearce, Chief Executive of Proteome Sciences. “It has long been our goal to provide clinicians the tools they need to provide early diagnosis of disease and better match molecular targeting medicines to the most likely responders. The output from this agreement should have a profound positive impact on the lives of large numbers of patients suffering from chronic diseases and, at the same time, provide considerable economic benefits to the health care system.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,900+ scientific posters on ePosters
  • More than 4,200+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Proteome Sciences Signs $2m Contract with Genting TauRx Diagnostic Centre
Contract to develop diagnostic panels to detect Alzheimer’s disease and monitor treatment efficacy.
Tuesday, September 30, 2014
Stroke Biomarker License to Randox
Stroke biomarker to develop and produce diagnostic tests that could increase by fivefold the number of patients treated for stroke.
Friday, April 06, 2012
Completion of Alzheimer’s Plasma Biomarker Study
The preliminary results demonstrate significant diagnostic and prognostic utilities.
Wednesday, April 04, 2012
Scientific News
Common Cell Transformed into Master Heart Cell
By genetically reprogramming the most common type of cell in mammalian connective tissue, researchers at the University of Wisconsin—Madison have generated master heart cells — primitive progenitors that form the developing heart.
Genetic Mutation that Prevents Diabetes Complications
The most significant complications of diabetes include diabetic retinal disease, or retinopathy, and diabetic kidney disease, or nephropathy. Both involve damaged capillaries.
Charting Kidney Cancer Metabolism
Changes in cell metabolism are increasingly recognized as an important way tumors develop and progress, yet these changes are hard to measure and interpret. A new tool designed by MSK scientists allows users to identify metabolic changes in kidney cancer tumors that may one day be targets for therapy.
Individuals' Medical Histories Predicted by their Noncoding Genomes
Researchers have found that analyzing mutations in regions of the genome that control genes can predict medical conditions such as hypertension, narcolepsy and heart problems.
'Molecular Movie' Opens Door to New Cancer Treatments
An international team of scientists led by the University of Liverpool has produced a 'structural movie' revealing the step-by-step creation of an important naturally occurring chemical in the body that plays a role in some cancers.
Custom Tuning Knobs to Turn Off Any Gene
Factory managers can improve productivity by telling workers to speed up, slow down or stop doing tangential tasks while assembling widgets. Unfortunately for synthetic biologists attempting to produce pharmaceuticals, microbes don’t respond to direction like human personnel.
Unique Mechanism for a High-Risk Leukemia
Researchers uncovered the aberrant mechanism underlying a notoriously treatment-resistant acute lymphoblastic leukemia subtype; findings offer lessons for understanding all cancers.
Genetically Mapping the Most Lethal E.Coli Strains
New approach could lead to fewer deaths, and new treatments.
The Spice of Life
Scientists discover important genetic source of human diversity.
Cytoskeleton Crew
Findings confirm sugar's role in helping cancers survive by changing cellular architecture.
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,900+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,200+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!